Dr. Robert Lutz, the Vice President of Translational Research & Development at ImmunoGen, speaks with Cambridge Healthtech Institute's Nicole Lyscom about the plenary keynote address he will deliver at PEGS Europe on November 6, 2013 in Lisbon, Portugal. In this interview, Dr. Lutz discusses antibody-drug conjugates, from bench to bedside and back, and the development efforts for the next generation of ADC candidates.